Ananda Krishna Karanam

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

M. Pai, N. Kandiah, K. Park, 2017, Reactions Weekly.

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis

D. Papanicolaou, V. S. Williams, L. Tankó, 2020, Neurology.

Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer’s Disease

J. Fuh, E. Ebenezer, S. Hameed, 2020, Journal of Alzheimer's disease reports.

Erenumab dosage for migraine prevention: An evidence‐based narrative review with recommendations

P. Winner, S. Tepper, A. Blumenfeld, 2022, Headache.

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

M. Weatherall, M. Ashina, A. Gantenbein, 2022, Headache.

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

M. Pai, N. Kandiah, K. Park, 2017, Reactions Weekly.

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

M. Pai, N. Kandiah, K. Park, 2017, Clinical interventions in aging.

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-Term Extension of RESILIENT.

D. Papanicolaou, V. S. Williams, L. Tankó, 2021, Neurology.